European Commission approved on Monday Use of Imvanex Vaccine Against monkeypox in the European Union, as well as in Iceland, Liechtenstein and Norway.
Danish company Bavarian Nordic The company has received approval from Brussels to increase the use of its smallpox vaccine and this includes monkeypox, as stated in a statement by the company and confirmed by community sources.
comes after approval by Brussels European Medicines Agency approval (EMA), through the Committee on Medicinal Products for Human Use (CHMP) in Europe, on 22 July to expand the application of Imvanex to protect the adult population against monkeypox virus.
The CHMP also recommended authorizing Imvanex for the safety of the people. disease caused by vaccinia virus, which are similar, but milder, than the symptoms of smallpox.
already managed
The vaccine was approved in the European Union since 2013 to prevent smallpox. Its application for monkeypox was not determined, Although several European countries are already administering it for this purpose after the outbreak that began months ago.
In this context, Paul Chaplin, President and CEO of Bavarian Nordic, indicated that the approval of the vaccine “Can significantly improve preparation” of countries against “emerging diseases” through structured planning.
Bavarian Nordic, to confirm efficacy of monkeypox vaccine Will collect data from an observational study Which will happen during the outbreak of monkeypox happening in Europe.
Monkeypox begins with fever, headache, muscle aches, tiredness, and swollen lymph nodes. The disease can be fatal, although it is usually milder than smallpox. It is transmitted from various wild animals, such as rodents and primates, to people, but also It can be transmitted between people through direct or indirect contact.
